Home » Newsletters » BioWorld Science

BioWorld Science

April 2, 2008

View Archived Issues

BioMimetic Therapeutics responds to FDA communication on Regranex safety review

New agents for treating neurological disorders disclosed in recent patents

Cysteine protease inhibitors reduce beta-amyloid, improve memory in Alzheimer's model

SAHA enhances anti-CD3 conditioning for allogeneic hematopoietic cell transplant

Conor and Cordis initiate RES-ELUTION clinical trial of sirolimus-eluting coronary stent

ARCA Discovery changes name to ARCA biopharma and plans to file NDA for bucindolol

Merck & Co. places on hold further patient enrollment in ACHIEVE study of Cordaptive

AstraZeneca stops JUPITER study of Crestor early due to unequivocal evidence of benefit

Crucell initiates phase II clinical trial of rabies monoclonal antibody

Acusphere licenses hydrophobic drug delivery system and AI-850 to Cephalon

DUSA completes enrollment in phase IIb trial of Levulan photodynamic therapy for acne

MediciNova initiates phase II clinical trial of MN-221 in asthma

DSMB supports continuation of Genta's phase III AGENDA trial of Genasense in melanoma

Recent patents describe new treatment options for endocrine disorders

AnGes files NDA in Japan for Collategene in critical limb ischemia

Novel peptide shows cardiac unloading properties without causing hypotension

InterMune reports top-line phase Ib ITMN-191 results in HCV

Relistor receives Canadian approval for opioid-induced constipation

Vivus and FDA agree on safety study and SPA for phase III trials of Luramist for HSDD

Avant reports positive results from phase II clinical trial of typhoid fever vaccine Ty-800

BAY-58-2667 shows promise in acute decompensated heart failure patients

Lysteria monocytogenes-based vaccine induces tumor regression in murine model of prostate cancer

Taranabant study shows weight loss, metabolic benefits after one year

Novel antiinfective agents reported in recent Saitama University and Actelion patents

TAK-475 development for hypercholesterolemia discontinued

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...